- In February 2020, Zoetis had announced the U.S. Food and Drug Administration (FDA) approval for Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets), the first once-monthly, chewable tablet in the U.S. This medication delivers all-in-one protection from heartworm disease, roundworm ticks, fleas, and hookworms. This combo medication builds on the proven success of Simparica (sarolaner) Chewables and demonstrates Zoetis' commitment to parasiticide innovation
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Class (Benzimidazoles, Piperazine), Target Pathogen (Ancylostoma Duodenale, Ascaris Lumbricoides, Enterobius Vermicularis, Trichuris Trichiura), Drugs (Miltefosine, Thiabendazole, Praziquantel, Mebendazole, Albendazole, Pyrantel, Ivermectin, Others), Application (Angiostrongylosis, Ascariasis, Capillariasis, Echinococcus, Gnathostomiasis, Liver Fluke, Moniliformis Infection, Trichostrongylosis, Enterobiasis, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Anthelmintics Market size was valued at USD 3.62 USD Billion in 2024.
The Global Anthelmintics Market is projected to grow at a CAGR of 8.42% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
